Effectiveness of piracetam in cortical myoclonus.
Identifieur interne : 004A01 ( Ncbi/Merge ); précédent : 004A00; suivant : 004A02Effectiveness of piracetam in cortical myoclonus.
Auteurs : P. Brown [Royaume-Uni] ; M J Steiger ; P D Thompson ; J C Rothwell ; B L Day ; M. Salama ; T. Waegemans ; C D MarsdenSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1993.
English descriptors
- KwdEn :
- Adult, Aged, Anticonvulsants (administration & dosage), Anticonvulsants (adverse effects), Cerebral Cortex (drug effects), Cerebral Cortex (physiopathology), Double-Blind Method, Drug Therapy, Combination, Electroencephalography (drug effects), Epilepsies, Myoclonic (drug therapy), Epilepsies, Myoclonic (physiopathology), Evoked Potentials, Somatosensory (drug effects), Evoked Potentials, Somatosensory (physiology), Female, Humans, Male, Middle Aged, Neurologic Examination (drug effects), Piracetam (administration & dosage), Piracetam (adverse effects).
- MESH :
- chemical , administration & dosage : Anticonvulsants, Piracetam.
- chemical , adverse effects : Anticonvulsants, Piracetam.
- drug effects : Cerebral Cortex, Electroencephalography, Evoked Potentials, Somatosensory, Neurologic Examination.
- drug therapy : Epilepsies, Myoclonic.
- physiology : Evoked Potentials, Somatosensory.
- physiopathology : Cerebral Cortex, Epilepsies, Myoclonic.
- Adult, Aged, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged.
Abstract
Twenty-one patients with disabling spontaneous, reflex, or action myoclonus due to various causes, who had shown apparent clinical improvement on introduction of piracetam, entered a placebo-controlled double-blind crossover trial of piracetam (2.4-16.8 g daily). All but one patient had electrophysiological evidence of cortical myoclonus. Patients were randomly allocated to a 14-day course of piracetam followed by identical placebo, or placebo followed by piracetam. Nineteen patients received piracetam/placebo in addition to their routine antimyoclonic treatment (carbamazepine, clonazepam, phenytoin, primidone, sodium valproate, or tryptophan plus isocarboxazid, alone or in combination) and two received piracetam/placebo as monotherapy. All patients were rated at the end of each treatment phase using stimulus sensitivity, motor, writing, functional disability, global assessment, and visual analogue scales. Ten of the 21 patients had to be rescued from the placebo phase of the trial because of a severe and intolerable exacerbation of their myoclonus. No patients required rescue from the piracetam phase of the double-blind trial. When the 21 patients were considered together, there was a significant improvement in motor, writing, functional disability, global assessment, and visual analogue scores during treatment with piracetam compared with placebo. The total rating score also improved significantly with piracetam, by a median of 22%. Piracetam, usually in combination with other antimyoclonic drugs, is a useful treatment for myoclonus of cortical origin.
DOI: 10.1002/mds.870080112
PubMed: 8419809
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004C70
- to stream PubMed, to step Curation: 004C70
- to stream PubMed, to step Checkpoint: 004C60
Links to Exploration step
pubmed:8419809Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effectiveness of piracetam in cortical myoclonus.</title><author><name sortKey="Brown, P" sort="Brown, P" uniqKey="Brown P" first="P" last="Brown">P. Brown</name><affiliation wicri:level="2"><nlm:affiliation>MRC Human Movement and Balance Unit, Institute of Neurology, London, England.</nlm:affiliation><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>MRC Human Movement and Balance Unit, Institute of Neurology, London</wicri:cityArea></affiliation></author><author><name sortKey="Steiger, M J" sort="Steiger, M J" uniqKey="Steiger M" first="M J" last="Steiger">M J Steiger</name></author><author><name sortKey="Thompson, P D" sort="Thompson, P D" uniqKey="Thompson P" first="P D" last="Thompson">P D Thompson</name></author><author><name sortKey="Rothwell, J C" sort="Rothwell, J C" uniqKey="Rothwell J" first="J C" last="Rothwell">J C Rothwell</name></author><author><name sortKey="Day, B L" sort="Day, B L" uniqKey="Day B" first="B L" last="Day">B L Day</name></author><author><name sortKey="Salama, M" sort="Salama, M" uniqKey="Salama M" first="M" last="Salama">M. Salama</name></author><author><name sortKey="Waegemans, T" sort="Waegemans, T" uniqKey="Waegemans T" first="T" last="Waegemans">T. Waegemans</name></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C D" last="Marsden">C D Marsden</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1993">1993</date><idno type="RBID">pubmed:8419809</idno><idno type="pmid">8419809</idno><idno type="doi">10.1002/mds.870080112</idno><idno type="wicri:Area/PubMed/Corpus">004C70</idno><idno type="wicri:Area/PubMed/Curation">004C70</idno><idno type="wicri:Area/PubMed/Checkpoint">004C60</idno><idno type="wicri:Area/Ncbi/Merge">004A01</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effectiveness of piracetam in cortical myoclonus.</title><author><name sortKey="Brown, P" sort="Brown, P" uniqKey="Brown P" first="P" last="Brown">P. Brown</name><affiliation wicri:level="2"><nlm:affiliation>MRC Human Movement and Balance Unit, Institute of Neurology, London, England.</nlm:affiliation><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>MRC Human Movement and Balance Unit, Institute of Neurology, London</wicri:cityArea></affiliation></author><author><name sortKey="Steiger, M J" sort="Steiger, M J" uniqKey="Steiger M" first="M J" last="Steiger">M J Steiger</name></author><author><name sortKey="Thompson, P D" sort="Thompson, P D" uniqKey="Thompson P" first="P D" last="Thompson">P D Thompson</name></author><author><name sortKey="Rothwell, J C" sort="Rothwell, J C" uniqKey="Rothwell J" first="J C" last="Rothwell">J C Rothwell</name></author><author><name sortKey="Day, B L" sort="Day, B L" uniqKey="Day B" first="B L" last="Day">B L Day</name></author><author><name sortKey="Salama, M" sort="Salama, M" uniqKey="Salama M" first="M" last="Salama">M. Salama</name></author><author><name sortKey="Waegemans, T" sort="Waegemans, T" uniqKey="Waegemans T" first="T" last="Waegemans">T. Waegemans</name></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C D" last="Marsden">C D Marsden</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1993" type="published">1993</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Anticonvulsants (administration & dosage)</term><term>Anticonvulsants (adverse effects)</term><term>Cerebral Cortex (drug effects)</term><term>Cerebral Cortex (physiopathology)</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Electroencephalography (drug effects)</term><term>Epilepsies, Myoclonic (drug therapy)</term><term>Epilepsies, Myoclonic (physiopathology)</term><term>Evoked Potentials, Somatosensory (drug effects)</term><term>Evoked Potentials, Somatosensory (physiology)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination (drug effects)</term><term>Piracetam (administration & dosage)</term><term>Piracetam (adverse effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anticonvulsants</term><term>Piracetam</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anticonvulsants</term><term>Piracetam</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cerebral Cortex</term><term>Electroencephalography</term><term>Evoked Potentials, Somatosensory</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Epilepsies, Myoclonic</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Evoked Potentials, Somatosensory</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Cerebral Cortex</term><term>Epilepsies, Myoclonic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Twenty-one patients with disabling spontaneous, reflex, or action myoclonus due to various causes, who had shown apparent clinical improvement on introduction of piracetam, entered a placebo-controlled double-blind crossover trial of piracetam (2.4-16.8 g daily). All but one patient had electrophysiological evidence of cortical myoclonus. Patients were randomly allocated to a 14-day course of piracetam followed by identical placebo, or placebo followed by piracetam. Nineteen patients received piracetam/placebo in addition to their routine antimyoclonic treatment (carbamazepine, clonazepam, phenytoin, primidone, sodium valproate, or tryptophan plus isocarboxazid, alone or in combination) and two received piracetam/placebo as monotherapy. All patients were rated at the end of each treatment phase using stimulus sensitivity, motor, writing, functional disability, global assessment, and visual analogue scales. Ten of the 21 patients had to be rescued from the placebo phase of the trial because of a severe and intolerable exacerbation of their myoclonus. No patients required rescue from the piracetam phase of the double-blind trial. When the 21 patients were considered together, there was a significant improvement in motor, writing, functional disability, global assessment, and visual analogue scores during treatment with piracetam compared with placebo. The total rating score also improved significantly with piracetam, by a median of 22%. Piracetam, usually in combination with other antimyoclonic drugs, is a useful treatment for myoclonus of cortical origin.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">8419809</PMID><DateCreated><Year>1993</Year><Month>02</Month><Day>11</Day></DateCreated><DateCompleted><Year>1993</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>1993</Year></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of piracetam in cortical myoclonus.</ArticleTitle><Pagination><MedlinePgn>63-8</MedlinePgn></Pagination><Abstract><AbstractText>Twenty-one patients with disabling spontaneous, reflex, or action myoclonus due to various causes, who had shown apparent clinical improvement on introduction of piracetam, entered a placebo-controlled double-blind crossover trial of piracetam (2.4-16.8 g daily). All but one patient had electrophysiological evidence of cortical myoclonus. Patients were randomly allocated to a 14-day course of piracetam followed by identical placebo, or placebo followed by piracetam. Nineteen patients received piracetam/placebo in addition to their routine antimyoclonic treatment (carbamazepine, clonazepam, phenytoin, primidone, sodium valproate, or tryptophan plus isocarboxazid, alone or in combination) and two received piracetam/placebo as monotherapy. All patients were rated at the end of each treatment phase using stimulus sensitivity, motor, writing, functional disability, global assessment, and visual analogue scales. Ten of the 21 patients had to be rescued from the placebo phase of the trial because of a severe and intolerable exacerbation of their myoclonus. No patients required rescue from the piracetam phase of the double-blind trial. When the 21 patients were considered together, there was a significant improvement in motor, writing, functional disability, global assessment, and visual analogue scores during treatment with piracetam compared with placebo. The total rating score also improved significantly with piracetam, by a median of 22%. Piracetam, usually in combination with other antimyoclonic drugs, is a useful treatment for myoclonus of cortical origin.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>MRC Human Movement and Balance Unit, Institute of Neurology, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steiger</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>P D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Rothwell</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Day</LastName><ForeName>B L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Salama</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Waegemans</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Marsden</LastName><ForeName>C D</ForeName><Initials>CD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>ZH516LNZ10</RegistryNumber><NameOfSubstance UI="D010889">Piracetam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000927">Anticonvulsants</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002540">Cerebral Cortex</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004569">Electroencephalography</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004831">Epilepsies, Myoclonic</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005073">Evoked Potentials, Somatosensory</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010889">Piracetam</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8419809</ArticleId><ArticleId IdType="doi">10.1002/mds.870080112</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li></region></list><tree><noCountry><name sortKey="Day, B L" sort="Day, B L" uniqKey="Day B" first="B L" last="Day">B L Day</name><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C D" last="Marsden">C D Marsden</name><name sortKey="Rothwell, J C" sort="Rothwell, J C" uniqKey="Rothwell J" first="J C" last="Rothwell">J C Rothwell</name><name sortKey="Salama, M" sort="Salama, M" uniqKey="Salama M" first="M" last="Salama">M. Salama</name><name sortKey="Steiger, M J" sort="Steiger, M J" uniqKey="Steiger M" first="M J" last="Steiger">M J Steiger</name><name sortKey="Thompson, P D" sort="Thompson, P D" uniqKey="Thompson P" first="P D" last="Thompson">P D Thompson</name><name sortKey="Waegemans, T" sort="Waegemans, T" uniqKey="Waegemans T" first="T" last="Waegemans">T. Waegemans</name></noCountry><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Brown, P" sort="Brown, P" uniqKey="Brown P" first="P" last="Brown">P. Brown</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A01 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004A01 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:8419809
|texte= Effectiveness of piracetam in cortical myoclonus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:8419809" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |